Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook

Eitemau Tebyg

• Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
  gan: Möhn, Nora, et al.
  Cyhoeddwyd: (2020)
• Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
  gan: Larkin, James, et al.
  Cyhoeddwyd: (2017)
• Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
  gan: Zhou, Shi, et al.
  Cyhoeddwyd: (2019)
• Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
  gan: Almutairi, Abdulaali R., et al.
  Cyhoeddwyd: (2020)
• Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
  gan: Friedman, Claire F., et al.
  Cyhoeddwyd: (2017)